A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 87 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 20 in phase 3, and was the 10th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 115th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2014, is one of 121 in phase 3, and was the 183rd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of asthma as documented by either:
Airway reversibility (FEV1 ≥12% and 200 mL) demonstrated at Visit 1, Visit 2, or Visit 3 using the Maximum Post-bronchodilator Procedure OR Documented reversibility in the previous 24 months prior to Visit 1 OR Airway hyperresponsiveness (PC20 FEV1 methacholine concentration ≤8mg/mL) documented in the previous 12 months prior to planned date of randomization OR Airflow variability in clinic FEV1 ≥20% between 2 consecutive clinic visits documented in the 12 months prior to the planned date of randomization (FEV1 recorded during an exacerbation should not be considered for this criterion).
All patients must have reversibility testing performed before randomization to establish a baseline characteristic.
If patients do not demonstrate airway reversibility at either Visit 1 or Visit 2 and this is needed to qualify the patient for randomization, the site should reiterate the need to withhold short- and long-acting bronchodilators prior to Visit 3 in an effort to meet this inclusion criterion.
Exclusion criteria:
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
Biological: Benralizumab
Placebo administered subcutaneously every 4 weeks
Biological: Placebo
Benralizumab administered subcutaneously every 4 weeks
Placebo subcutaneously on study week 0 until study week 24 inclusive.
Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control
Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.
Time frame: Week 28
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control
Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
Time frame: Week 28
Number and Percentage of Patients With ≥1 Asthma Exacerbation
Number and percentage of patients with at least one post randomisation asthma exacerbation.
Time frame: Immediately following the randomisation through Study Week 28
Time to the First Asthma Exacerbation
Time to the first occurrence of asthma exacerbation post randomisation
Time frame: The time from randomisation to the date of first asthma exacerbation over 28 weeks
Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit
Time to the first exacerbation requiring hospitalization or ER visit post randomisation
Time frame: The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.
The Annualized Rate of Asthma Exacerbation
The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.
Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization
The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.
Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
Number of Days in Hospital Due to Asthma
Number of days in hospital due to asthma, if none, 0 day is considered
Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
Change From Baseline to Week 28 in Pre-bronchodilator FEV1
Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Asthma Symptom Scores (Total)
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)
Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)
Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Rescue Medication Use
Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of day inhaler puffs + 2 x \[number of day nebulizer times\].
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)
Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)
Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication
Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.
Time frame: Change from baseline at week 28
Change From Baseline to Week 28 in ACQ-6
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: Change from baseline at week 28
ACQ-6 Responders (Improvement) at Week 28
Improvement is defined as ACQ-6 (End of treatment - baseline) \<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.
Time frame: Week 28
Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
Time frame: Change from baseline at week 28
AQLQ(s)+12 Responders (Improvement) at Week 28
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.
Time frame: Week 28
Extent of Exposure
Duration of exposure from first dose date to last dose date.
Time frame: From first dose to Week 24
Serum Concentration of Benralizumab
Pre-dose serum concentrations at each visit
Time frame: Pre-first dose to Week 36
Anti-drug Antibody Response
Number and percentage of patients in different ADA response categories
Time frame: From baseline to follow-up Week 36
Percent Change From Baseline in Blood Eosinophil Counts
Percent change from baseline in blood eosinophil counts at week 28
Time frame: Change from baseline at Week 28
Total Lung Capacity
Change from baseline in total lung capacity
Time frame: From baseline to Week 28
Residual Volume
Change from baseline in residual volume
Time frame: From baseline to Week 28
Vital Capacity
Change from baseline in vital capacity
Time frame: From baseline to Week 28
Functional Residual Capacity
Change from baseline in functional residual capacity
Time frame: From baseline to Week 28
Inspiratory Capacity
Change from baseline in inspiratory capacity
Time frame: From baseline to Week 28
| Milestone | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Started | 72 | 73 | 75 |
| Completed | 68 | 69 | 72 |
| Not completed | 4 | 4 | 3 |
| Withdrew: Study specific withdrawal criteria | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Death | 0 | 2 | 0 |
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Percent | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control | 75.00 (50.00 to 83.30) | 75.00 (60.00 to 87.50) | 25.00 (0.00 to 33.30) |
Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| >=90% reduction | 24 | 27 | 9 |
| >=75% reduction | 38 | 37 | 15 |
| >=50% reduction | 48 | 48 | 28 |
| >0% reduction | 55 | 58 | 40 |
| No change or any increase | 17 | 15 | 35 |
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Percent | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL | 75.00 (60.00 to 100.00) | 75.00 (60.00 to 91.70) | 0.00 (0.00 to 28.60) |
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control | 48 | 48 | 28 |
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control | 22 | 22 | 8 |
Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control. | 22 | 25 | 38 |
Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control | 44 | 43 | 25 |
Number and percentage of patients with at least one post randomisation asthma exacerbation.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Number and Percentage of Patients With ≥1 Asthma Exacerbation | 19 | 17 | 39 |
Time to the first occurrence of asthma exacerbation post randomisation
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Time to the First Asthma Exacerbation | NA (NA to NA) | NA (NA to NA) | 155 (111 to NA) |
Time to the first exacerbation requiring hospitalization or ER visit post randomisation
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.
| events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Annualized Rate of Asthma Exacerbation | 0.83 (0.55 to 1.26) | 0.54 (0.34 to 0.88) | 1.83 (1.33 to 2.50) |
The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.
| events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization | 0.14 (0.05 to 0.38) | 0.02 (0.00 to 0.18) | 0.32 (0.16 to 0.65) |
Number of days in hospital due to asthma, if none, 0 day is considered
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Number of Days in Hospital Due to Asthma | 0.3 ± 1.41 | 0.5 ± 3.86 | 1.2 ± 6.66 |
Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Pre-bronchodilator FEV1 | 0.230 ± 0.429 | 0.255 ± 0.508 | 0.114 ± 0.401 |
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Asthma Symptom Scores (Total) | -0.58 ± 1.03 | -0.77 ± 1.03 | -0.58 ± 1.03 |
Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime) | -0.32 ± 0.56 | -0.44 ± 0.52 | -0.32 ± 0.57 |
Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime) | -0.27 ± 0.51 | -0.34 ± 0.54 | -0.27 ± 0.54 |
Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of day inhaler puffs + 2 x \[number of day nebulizer times\].
| number of puffs per day | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Rescue Medication Use | -1.39 ± 2.86 | -2.58 ± 4.36 | -1.07 ± 2.86 |
Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.
| Liter/min | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow) | 32.697 ± 89.457 | 43.022 ± 73.303 | 10.884 ± 69.356 |
Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data
| Liter/min | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow) | 21.885 ± 83.136 | 34.157 ± 69.287 | 2.933 ± 72.302 |
Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.
| Proportion | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication | -0.158 ± 0.283 | -0.2 ± 0.337 | -0.186 ± 0.344 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 28 in ACQ-6 | -0.86 ± 0.95 | -1.09 ± 1.09 | -0.68 ± 1.10 |
Improvement is defined as ACQ-6 (End of treatment - baseline) \<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| ACQ-6 Responders (Improvement) at Week 28 | 41 ± 0.95 | 46 ± 1.09 | 41 ± 1.10 |
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline at Week 28 in AQLQ(S)+12 (Overall) | 0.90 ± 0.93 | 1.05 ± 1.04 | 0.67 ± 1.10 |
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| AQLQ(s)+12 Responders (Improvement) at Week 28 | 43 ± 0.95 | 44 ± 1.09 | 39 ± 1.10 |
Duration of exposure from first dose date to last dose date.
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Extent of Exposure | 162.53 ± 30.09 | 159.77 ± 35.781 | 167.05 ± 10.697 |
Pre-dose serum concentrations at each visit
| ng/mL | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Baseline (n=69, 71) | NA ± NA | NA ± NA | — |
| Week 4 (n=67, 71) | 804.37 ± 52.77 | 721.42 ± 52.30 | — |
| week 8 (n=66, 69) | 1152.96 ± 53.16 | 1019.65 ± 89.51 | — |
| Week 12 (n=68, 67) | 1319.14 ± 66.05 | 1057.91 ± 125.74 | — |
| Week 16 (n=67,67) | 1337.98 ± 118.90 | 303.54 ± 144.53 | — |
| Week 24 (n=65, 66) | 1162.62 ± 151.35 | 185.17 ± 278.32 | — |
| Week 28 (n=65, 65) | 1125.96 ± 173.79 | 684.57 ± 205.67 | — |
| Week 36 (n=2, 4) | 11.11 ± 2140.87 | 5.92 ± 1230.68 | — |
Number and percentage of patients in different ADA response categories
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Positive at any visit | 5 | 7 | 6 |
| Baseline and Post-baseline Postive | 0 | 0 | 3 |
| Only post-baseline positive | 5 | 6 | 3 |
| Only baseline positive | 0 | 1 | 0 |
| Persistently positive | 4 | 6 | 5 |
| Transient positive | 1 | 0 | 1 |
Percent change from baseline in blood eosinophil counts at week 28
| percent change | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Blood Eosinophil Counts | -97.4 ± 12.93 | -94.9 ± 16.54 | 45.5 ± 239.51 |
Change from baseline in total lung capacity
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Week 12 (n=17, 23, 17) | -0.02 ± 0.95 | -0.07 ± 0.68 | -0.30 ± 1.08 |
| Week 28 (n=14, 18, 15) | 0.11 ± 1.31 | -0.21 ± 0.70 | -0.47 ± 1.47 |
Change from baseline in residual volume
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Week 12 (n=17, 23, 17) | 0.02 ± 1.00 | -0.22 ± 0.74 | -0.35 ± 1.03 |
| Week 28 (n=14, 18, 15) | 0.07 ± 1.34 | -0.31 ± 0.71 | -0.41 ± 1.27 |
Change from baseline in vital capacity
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Week 12 (n=17, 24, 18) | 0.15 ± 0.80 | 0.18 ± 0.35 | 0.13 ± 0.89 |
| Week 28 (n=14, 18, 15) | 0.15 ± 0.41 | 0.11 ± 0.48 | -0.08 ± 0.41 |
Change from baseline in functional residual capacity
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Week 12 (n=17,23, 18) | -0.05 ± 1.06 | -0.09 ± 0.74 | -0.38 ± 0.99 |
| Week 28 (n=13,18, 15) | -0.15 ± 1.49 | -0.26 ± 0.74 | -0.43 ± 1.25 |
Change from baseline in inspiratory capacity
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Week 12 (n=17, 23, 17) | 0.44 ± 1.22 | 0.14 ± 0.88 | -0.01 ± 0.40 |
| Week 28 (n=14, 17, 15) | 0.52 ± 1.16 | 0.09 ± 1.01 | -0.02 ± 0.40 |
Collected over Include events occurred from the start of study treatment to the end of study (up to 36 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg q.4 Weeks | — | 7/72 (9.7%) | 34/72 (47.2%) |
| Benra 30 mg q.8 Weeks | — | 7/73 (9.6%) | 34/73 (46.6%) |
| Placebo | — | 14/75 (18.7%) | 49/75 (65.3%) |
| Event | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/72 | 1/73 | 4/75 |
| PneumoniaInfections and infestations | 0/72 | 2/73 | 3/75 |
| Status asthmaticusRespiratory, thoracic and mediastinal disorders | 0/72 | 0/73 | 3/75 |
| InfluenzaInfections and infestations | 0/72 | 0/73 | 2/75 |
| Umbilical herniaGastrointestinal disorders | 1/72 | 0/73 | 0/75 |
| Adverse drug reactionGeneral disorders | 1/72 | 0/73 | 0/75 |
| HypersensitivityImmune system disorders | 1/72 | 0/73 | 0/75 |
| Urinary tract infection bacterialInfections and infestations | 1/72 | 0/73 | 0/75 |
| UrosepsisInfections and infestations | 1/72 | 0/73 | 0/75 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/72 | 0/73 | 0/75 |
| Event | Benra 30 mg q.4 Weeks | Benra 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/72 | 12/73 | 15/75 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/72 | 1/73 | 14/75 |
| BronchitisInfections and infestations | 5/72 | 8/73 | 12/75 |
| SinusitisInfections and infestations | 5/72 | 4/73 | 8/75 |
| RhinitisInfections and infestations | 2/72 | 6/73 | 2/75 |
| HeadacheNervous system disorders | 5/72 | 6/73 | 4/75 |
| Upper respiratory tract infectionInfections and infestations | 4/72 | 5/73 | 5/75 |
| InfluenzaInfections and infestations | 3/72 | 1/73 | 5/75 |
| Oral candidiasisInfections and infestations | 0/72 | 0/73 | 4/75 |
| Back painMusculoskeletal and connective tissue disorders | 2/72 | 2/73 | 4/75 |
| Age, Continuous(Years) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Mean | 50.2 ± 12.0 | 52.9 ± 10.1 | 49.9 ± 11.7 | 51.0 ± 11.3 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Female | 40 | 47 | 48 | 135 |
| Male | 32 | 26 | 27 | 85 |
Ran from Apr 2014 to primary completion in Aug 2016, 27 months.
Results were first posted in Oct 2017, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab